Increased Angiogenesis Protects against Adipose Hypoxia and Fibrosis in Metabolic Disease-resistant 11β-Hydroxysteroid Dehydrogenase Type 1 (HSD1)-deficient Mice

被引:72
|
作者
Michailidou, Zoi [1 ]
Turban, Sophie [2 ]
Miller, Eileen [2 ]
Zou, Xiantong [2 ]
Schrader, Joerg [1 ]
Ratcliffe, Peter J. [3 ]
Hadoke, Patrick W. F. [2 ]
Walker, Brian R. [2 ]
Iredale, John P. [1 ]
Morton, Nicholas M. [2 ]
Seckl, Jonathan R. [2 ]
机构
[1] Univ Edinburgh, Queens Med Res Inst, MRC, Ctr Inflammat Res, Edinburgh EH16 4TJ, Midlothian, Scotland
[2] Univ Edinburgh, Queens Med Res Inst, Univ British Heart Fdn BHF, Ctr Cardiovasc Sci, Edinburgh EH16 4TJ, Midlothian, Scotland
[3] Univ Oxford, Nuffield Dept Clin Med, Oxford OX3 7BN, England
基金
英国惠康基金;
关键词
INDUCED VISCERAL OBESITY; INDUCIBLE FACTOR 1-ALPHA; GENE-EXPRESSION; GLUCOCORTICOID-RECEPTOR; TISSUE HYPOXIA; INFLAMMATION; INSULIN; CELLS; HIF-1-ALPHA; PATHWAY;
D O I
10.1074/jbc.M111.259325
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In obesity, rapidly expanding adipose tissue becomes hypoxic, precipitating inflammation, fibrosis, and insulin resistance. Compensatory angiogenesis may prevent these events. Mice lacking the intracellular glucocorticoid-amplifying enzyme 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta HSD1(-/-)) have "healthier" adipose tissue distribution and resist metabolic disease with diet-induced obesity. Here we show that adipose tissues of 11 beta HSD1(-/-) mice exhibit attenuated hypoxia, induction of hypoxia-inducible factor (HIF-1 alpha) activation of the TGF beta/Smad3/alpha-smooth muscle actin (alpha-SMA) signaling pathway, and fibrogenesis despite similar fat accretion with diet-induced obesity. Moreover, augmented 11 beta HSD1(-/-) adipose tissue angiogenesis is associated with enhanced peroxisome proliferator-activated receptor gamma (PPAR gamma)-inducible expression of the potent angiogenic factors VEGF-A, apelin, and angiopoietin-like protein 4. Improved adipose angiogenesis and reduced fibrosis provide a novel mechanism whereby suppression of intracellular glucocorticoid regeneration promotes safer fat expansion with weight gain.
引用
收藏
页码:4188 / 4197
页数:10
相关论文
共 50 条
  • [31] Expression of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity
    Tomlinson, JW
    Sinha, B
    Bujalska, I
    Hewison, M
    Stewart, PM
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (12): : 5630 - 5635
  • [32] Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11β-hydroxysteroid dehydrogenase-1 (HSD1) inhibitor in humans: liver and adipose tissue 11β-HSD1 inhibition after acute and multiple administrations over 2 weeks
    Freude, S.
    Heise, T.
    Woerle, H. -J.
    Jungnik, A.
    Rauch, T.
    Hamilton, B.
    Schoelch, C.
    Huang, F.
    Graefe-Mody, U.
    DIABETES OBESITY & METABOLISM, 2016, 18 (05): : 483 - 490
  • [33] Comparison of a homology model and the crystallographic structure of human 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) in a structure-based identification of inhibitors
    Laurence Miguet
    Ziding Zhang
    Maryse Barbier
    Martin G. Grigorov
    Journal of Computer-Aided Molecular Design, 2006, 20 : 67 - 81
  • [34] Comparison of a homology model and the crystallographic structure of human 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) in a structure-based identification of inhibitors
    Miguet, Laurence
    Zhang, Ziding
    Barbier, Maryse
    Grigorov, Martin G.
    JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2006, 20 (02) : 67 - 81
  • [35] Identification and optimisation of 3,3-dimethylazetidin-2-ones as potent and selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1)
    McCoull, William
    Augustin, Martin
    Blake, Caroline
    Ertan, Anne
    Kilgour, Elaine
    Krapp, Stephan
    Moore, Jane E.
    Newcombe, Nicholas J.
    Packer, Martin J.
    Rees, Amanda
    Revill, John
    Scott, James S.
    Selmi, Nidhal
    Gerhardt, Stefan
    Ogg, Derek J.
    Steinbacher, Stefan
    Whittamore, Paul R. O.
    MEDCHEMCOMM, 2014, 5 (01) : 57 - 63
  • [36] Discovery of the clinical candidate BMS-816336, an adamantyl acetamide based 11β-hydroxysteroid dehydrogenase type-1 (11β-HSD1) inhibitor
    Ye, Xiang-Yang
    Chen, Stephanie
    Wu, Shung
    Yoon, David
    Wang, Haixia
    Hong, Zhengqiu
    Oconnor, Stephen
    Li, James
    Li, Jun
    Walker, Steven
    Kennedy, Lawrence
    Apedo, Atsu
    Nayeem, Akbar
    Sheriff, Steven
    Morin, Paul
    Camac, Daniel
    Harrity, Thomas
    Zebo, Rachel
    Taylor, Joseph
    Morgan, Nathan
    Ponticiello, Randolph
    Golla, Rajasree
    Seethala, Ramakrishna
    Wang, Mengmeng
    Harper, Timothy
    Sleczka, Bogdan
    He, Bin
    Kirby, Mark
    DiMarco, John
    Scaringe, Raymond
    Hanson, Ronald
    Guo, Zhiwei
    Li, Jianqing
    Sun, Jung-Hui
    Wong, Michael
    Chen, Bang-Chi
    Haque, Lauren
    Leahy, David
    Chan, Collin
    Li, Yi-Xin
    Zvyaga, Tatyana
    Hansen, Lars
    Patel, Chirag
    Gordon, David
    Robl, Jeffrey
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 249
  • [37] Tissue production of cortisol by 11β-hydroxysteroid dehydrogenase type 1 and metabolic disease
    Walker, Brian R.
    Andrew, Ruth
    STRESS, OBESITY, AND METABOLIC SYNDROME, 2006, 1083 : 165 - 184
  • [38] Substituted 1,2,4-oxodiazoles as Potent Inhibitors of Human 11β - hydroxysteroid Dehydrogenase Type 1 (11β-HSD1): Virtual Screening and Docking Results
    Ziolkovskiy, Dmitry V.
    Lipson, Victoria V.
    Nikitina, Anastasia D.
    Chebanov, Valentin A.
    LETTERS IN DRUG DESIGN & DISCOVERY, 2016, 13 (03) : 226 - 233
  • [39] Adipose tissue-targeted 11β-hydroxysteroid dehydrogenase type 1 inhibitor protects against diet-induced obesity
    Liu, Juan
    Wang, Long
    Zhang, Aisen
    Di, Wenjuan
    Zhang, Xiao
    Wu, Lin
    Yu, Jing
    Zha, Juanmin
    Lv, Shan
    Cheng, Peng
    Hu, Miao
    Li, Yujie
    Qi, Hanmei
    Ding, Guoxian
    Zhong, Yi
    ENDOCRINE JOURNAL, 2011, 58 (03) : 199 - 209
  • [40] Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™)
    Webster, Scott P.
    McBride, Andrew
    Binnie, Margaret
    Sooy, Karen
    Seckl, Jonathan R.
    Andrew, Ruth
    Pallin, T. David
    Hunt, Hazel J.
    Perrior, Trevor R.
    Ruffles, Vincent S.
    Ketelbey, J. William
    Boyd, Alan
    Walker, Brian R.
    BRITISH JOURNAL OF PHARMACOLOGY, 2017, 174 (05) : 396 - 408